LIFECORE BIOMEDICAL, INC. DE (LFCR): Nasdaq/NYSE listing notice — Lifecore receives Nasdaq delisting notice for late FY23 10-K filing

LIFECORE BIOMEDICAL, INC. DE

Notice received Aug 17, 2023; must submit compliance plan by Oct 16, 2023.
Plan acceptance could extend filing deadline to Feb 12, 2024.
No immediate effect on listing or trading on Nasdaq Global Select Market.
Company states it is working diligently to file Form 10-K promptly.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

August 17, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediate effect

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-23-000106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.